The median progression-free survival (PFS) was 10–14 months with first-generation or second-generation TKI (6–8) and 18.9 months with third-generation EGFR-TKIs for patients with EGFR mutant advanced NSCLC in first-line treatment (9). Here, EGFR is linked to non-small cell lung carcinoma.